Yahoo Web Search

Search results

1. • • Prometheus (RXDX) is set to be acquired by Merck for $11 billion, adding Prometheus' lead product candidate, PRA023, to Merck's portfolio.
     finance.yahoo.com/news/prometheus-rxdx-stock-surges-70-125612569.html

     Prometheus (RXDX) Stock Surges 70% on Buyout Offer From Merck

2. People also ask

   Does Merck own Prometheus?

   • Additional Transaction Details Under the terms of the acquisition agreement, Merck, through a subsidiary, has acquired all outstanding shares of Prometheus for $200.00 per share in cash for a total equity value of approximately $10.8 billion.

   Merck Completes Acquisition of Prometheus Biosciences, Inc

   www.businesswire.com/news/home/20230615914242/en/Merck-Completes-Acquisition-of-Prometheus-Biosciences-Inc.

   See all results for this question

   Who is Prometheus Biosciences?

   • About Prometheus Biosciences Prometheus Biosciences, Inc. is a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of immune-mediated diseases.

   Merck Strengthens Immunology Pipeline with Acquisition of Prometheus Biosciences, Inc…

   www.businesswire.com/news/home/20230416005034/en/Merck-Strengthens-Immunology-Pipeline-with-Acquisition-of-Prometheus-Biosciences-Inc.

   See all results for this question

   Who owns Prometheus Software?

   • Founded in 1998, Prometheus makes plant maintenance operations and optimization software for sectors including oil and gas, paper, mining and metals and utilities, according to its website. Genstar bought a majority stake in the company for more than $1 billion from Francisco Partners in 2019 and had explored a sale of the company in 2022.

   Advent Is Said to Near Deal for Stake in Prometheus Group - Bloomberg

   www.bloomberg.com/news/articles/2024-05-23/advent-is-said-to-near-deal-for-prometheus-software-firm-stake

   See all results for this question

   What happened to Prometheus?

   • Prometheus is now a wholly-owned subsidiary of Merck and the common stock of Prometheus will no longer be listed or traded on the Nasdaq Global Market. “ The Prometheus acquisition accelerates our growing presence in immunology, augments our diverse pipeline and increases our ability to deliver patient value.

   Merck Completes Acquisition of Prometheus Biosciences, Inc

   www.businesswire.com/news/home/20230615914242/en/Merck-Completes-Acquisition-of-Prometheus-Biosciences-Inc.

   See all results for this question

3. www.bloomberg.com › news › articlesAdvent Is Said to Near Deal for Stake in Prometheus Group ...

   www.bloomberg.com › news › articles

   • Cached

   May 23, 2024 · Buyout firm Advent International is nearing a deal to acquire a stake in Prometheus Group in a transaction that could value the industrial software company at more than $4 billion,...

4. www.businesswire.com › news › homeMerck Completes Acquisition of Prometheus Biosciences, Inc.

   www.businesswire.com › news › home

   • Cached

   Jun 16, 2023 · Prometheus is now a wholly-owned subsidiary of Merck and the common stock of Prometheus will no longer be listed or traded on the Nasdaq Global Market.

5. www.reuters.com › markets › dealsMerck to buy Prometheus Biosciences for about $11 billion

   www.reuters.com › markets › deals

   Apr 16, 2023 · April 16 (Reuters) - Merck & Co (MRK.N) said on Sunday it will buy Prometheus Biosciences Inc (RXDX.O) for about $10.8 billion, picking up a promising experimental treatment for ulcerative...

6. www.businesswire.com › news › homeMerck Strengthens Immunology Pipeline with Acquisition of ...

   www.businesswire.com › news › home

   • Cached

   Apr 16, 2023 · Prometheus Biosciences, Inc. is a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and...

7. www.fool.com › investing › 2022/12/08Why Shares of Prometheus Biosciences Are Soaring This Week

   www.fool.com › investing › 2022/12/08

   • Cached

   Dec 8, 2022 · Prometheus Biosciences(RXDX) saw its shares rise this week as much as 168.7% by early Thursday, according to data from S&P Global Intelligence. The clinical-stage biotech focuses on inflammatory...

8. www.marketwatch.com › story › prometheus-sharesPrometheus shares rally 177% as it prepares to move drug into ...

   www.marketwatch.com › story › prometheus-shares

   Dec 7, 2022 · Shares of Prometheus Biosciences Inc. soared 177.0% in premarket trading on Wednesday after the company said it will advance an experimental therapy into...